Asieris
is a China-based biopharmaceutical firm that develops and commercializes novel anti-cancer therapies for the treatment of genitourinary tumors... Read moreAsieris
is a China-based biopharmaceutical firm that develops and commercializes novel anti-cancer therapies for the treatment of genitourinary tumors... Read more
News
Jan 07, 2024
MarketScreener
Asieris: Certain A Shares of Jiangsu Yahong Meditech Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-JAN-2024.
Jul 06, 2023
FinanzNachrichten
Asieris: Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China
May 18, 2023
StreetInsider
Press Release: Asieris : Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer
Nov 10, 2022
StreetInsider
Press Release: Asieris : Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
Apr 14, 2022
Markets Insider
Asieris: Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy
Feb 11, 2022
FinanzNachrichten
Asieris: Photocure Partner Asieris announces Approval to conduct a Phase III Clinical Trial for Hexvix in China
Jun 15, 2021
ChinaBio Today
Asieris: Asieris to Start US Combination Trial of MetAP2 Inhibitor for Bladder Cancer
Nov 18, 2020
Equal Ocean
Asieris: Drug Innovator Asieris Nabs CNY 700 Million Series D
Nov 12, 2020
Equal Ocean
Asieris: Drug Innovator Asieris Nabs CNY 700 Million Series D
Nov 11, 2020
MarketScreener
Asieris: Photocure : Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702 (Cevira)
